声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。7月14日,NMPA官网显示,创新药港股上市公司中国抗体的舒西利单抗注射液(SM03,Suciraslimab)收到通知件,原因未知,本次申报的适应症为:用于治疗类风湿关节炎(RA)。据悉,该项申请为中国抗体自成立以来首项提交的上市申请。SM03(...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。7月14日,NMPA官网显示,创新药港股上市公司中国抗体的舒西利单抗注射液(SM03,Suciraslimab)收到通知件,原因未知,本次申报的适应症为:用于治疗类风湿关节炎(RA)。据悉,该项申请为中国抗体自成立以来首项提交的上市申请。SM03(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.